4//SEC Filing
Adaptimmune Therapeutics PLC 4
Accession 0001104659-16-090657
$ADAPCIK 0001621227operating
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 4:30 PM ET
Size
6.0 KB
Accession
0001104659-16-090657
Insider Transaction Report
Form 4
Binder-Scholl Gwendolyn Knowlton
EVP, Adaptimmune LLC
Transactions
- Award
Option to purchase Ordinary Shares
2016-01-18+704,961→ 704,961 totalExercise: $1.27Exp: 2026-01-18→ Ordinary Shares (704,961 underlying)
Footnotes (2)
- [F1]The exercise price was converted from GBP0.89 based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the business day prior to the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise.
- [F2]Exercisable as to 176,240 Ordinary Shares on January 18, 2017 and will be exercisable as to the remainder in monthly installments of 14,686 Ordinary Shares on the eighteenth of each month from February 18, 2017 through December 18, 2019, and in one installment of 14,711 Ordinary Shares on January 18, 2020.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeoperating
IncorporatedUnited Kingdom
Related Parties
1- filerCIK 0001621227
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 4:30 PM ET
- Size
- 6.0 KB